Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance
Exicure, Inc. announced it will issue approximately 172,058 shares of common stock to GPCR Therapeutics to settle a $1 million clinical milestone payment triggered by completion of a Phase 2 trial for Burixafor. This equity issuance allows Exicure to preserve cash and maintain financial flexibility as the company explores strategic alternatives fol…